Last reviewed · How we verify
Trumenba (trumenba)
Trumenba (generic name: trumenba) is a Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains Vaccine drug developed by Pfizer Inc.. It is currently in preclinical development.
Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains
Trumenba is a vaccine antigen used to prevent infection by Neisseria meningitidis, specifically targeting serogroup B. It works by inducing an immune response against the factor H binding protein of Neisseria meningitidis.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | trumenba |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains |
| Modality | Vaccine |
| Therapeutic area | Infectious Disease |
| Phase | preclinical |
Approved indications
Pipeline indications
- Neisseria Meningitidis — preclinical
Common side effects
Key clinical trials
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age (Phase 3)
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infant (Phase 2)
- A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents (Phase 2)
- A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and (N/A)
- Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults (Phase 1/2)
- Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immu (Phase 4)
- Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults (Phase 1)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trumenba CI brief — competitive landscape report
- Trumenba updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Trumenba
What is Trumenba?
How does Trumenba work?
Who makes Trumenba?
What is the generic name of Trumenba?
What drug class is Trumenba in?
What development phase is Trumenba in?
Related
- Drug class: All Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing